MUMBAI (Xinhua): Glenmark Pharmaceuticals has become the first Indian company to launch anti-viral drug Favipiravir for the treatment of mild to moderate Covid-19 patients in the domestic market following the manufacturing approval from the drug regulator, a company statement said.
Launched under the brand name FabiFlu, the oral drug will be available as a prescription-based medication for US$1.35 per tablet.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!